Navigation Links
Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting

#18064

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic therapy, Vidaza(R); a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

For more information or complete prescribing information about Vidaza, please call 1-866-PHARMION.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

The anticipated presentations described in this release will contain forward-looking statements, including summary statements relating to the results of clinical trials involving Pharmion's marketed and pipeline products. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. The clinical trials that are the subject of the presentations described in this release are being conducted by independent investigators and Pharmion does not control and cannot predict the final results of those trials. Top line results may not be confirmed upon full analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Pharmion's products may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the y
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:11/6/2009)... -- Philips Respironics applauds the efforts of th... to raise awareness about an important public heal... release of the first-ever government study to mon...s a milestone in quantifying the size and scope of...stry leader and sleep therapy manufacturer, Philip...
(Date:11/6/2009).../ -- Cyberonics, Inc. (Nasdaq: CYBX ) today annou...s for the second quarter ended October 23, 2009 of...y, November 18, 2009 at 5:00 PM EST. The company ...sults on Thursday, November 19, 2009 at 9:00 AM ES... Conference Call Instructions ,, To listen to...
(Date:11/6/2009)... , - Trial Will Compare NXL103 With Leadi...-Resistant Staphylococcus Aureus (MRSA) Infections...ompany focused on the discovery and,development of...icant global,problem of microbial resistance, anno...ial NXL103 (flopristin/linopristin), has started a...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 1Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 2Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 3Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 4Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 5Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 6Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 7Angiotechs Licensee Cook Medical Announces CE Mark Approval and European Launch of the Zilver 28R 29 PTX 28R 29 Stent 13489 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 1DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 2DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 3DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 5DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 6DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 7DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 9DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 10DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 11DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 12DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 13Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 1Rockport Healthcare Group Continues to Grow Coverage Area With New Work Comp Network Certification in Georgia 54149 2
...e many, clinical studies are few, NEW YORK, Aug. ...that a limited amount of clinical research exists,...r (OTC) anti-aging,products. The study is publishe...urgery Journal, the official peer-reviewed journal...gery (ASAPS). OTC anti-aging products represent a...
...tional Stem,Cell Holding, Inc. (OTC: NHGI.PK), tod...y, and Jacob Cohen, have discovered biomaterial de...s to promote tissue repair in,various wound care a...ced that while using its,proprietary embryonic ste...,group of biomaterials that in preclinical studies...
Other Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 2National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair 3
(Date:11/8/2009)...people in the Western District of Pennsylvania awa...uffering for a medical malpractice case. Attorney...of Thomas E. Crenney and Associates, LLC handled t...ky and against the Uniontown Hospital. The woman ...omy at age 18. , Pittsbur...
(Date:11/8/2009)...battle is won," said Dr. Charmaine Yoest. ,, W...vote of 240-194, the Stupak-Ellsworth-Pitts-Kaptur...bortion mandates and funding in HR 3962 passed on ...ction President and CEO Dr. Charmaine Yoest said, ...e pro-life Americans across this country who have ...
(Date:11/8/2009)...SNewswire/ -- USAction this evening hailed passage...ich will make health care more affordable for cons...crease access to health care for millions of Ameri...lt, FDR and Harry Truman would be proud," said USA... ranks among our country,s proudest achievements. ...
(Date:11/8/2009)... 3961 to Secure the Stability of Medicare ,, H...t Attributable to: J. James Rohack, M.D., Presiden...tp://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO... health reform bill, which will help improve the h... for swift passage of H.R. 3961 to secure the stab...
(Date:11/8/2009)...ealth Care Reform Bill ,, Critical legislatio...all Americans ,, CHICAGO, Nov. 7 /PRNewswire-U...presentatives passed by a vote of 220-215, critica...then Medicare for seniors and end discrimination b...icans out of affordable health coverage. ,, T...
Breaking Medicine News(10 mins):Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3
... for the festive season comprise most of the dengu...ted with the mosquito-borne virus so far.// ... threat of dengue in the state. Most of the ...pcoming Diwali and Chath festivals. In some ...
... to controlling diabetes, says former Pakistan cri...Diabetes can be managed by maintaining a healthy l...r medication and regular monitoring of blood sugar...icketer was speaking at the Accu-Chek Inspiration ...
...y Prize 2007 was awarded to a UK researcher who ha...n that could help to single out somebody's voice i...her and also responsible for training the brain to...most frequently encountered difficulty by over 9 m...
...out huge backlogs of patients for important surger..., who have begun investigating the issue. Accordi...mies, colonoscopies and gallbladder surgeries have...n Medical Association to investigate thoroughly du...
...health revolution that offers cures for cancer, re...alk again.// This is the opinion of Australia’... advances which they consider will transform lives...bined their expertise to look into the future for ...
...in a particular brain area of patients afflicted w...ed// at the Laboratory for Cognitive Neuroscience ...Williams syndrome is a rare genetic disorder where...e, said: "Understanding the connections between mi...
Other Medicine News:Health News:Migrant Bihar Labourers Bring Dengue Home 2Health News:Healthy Lifestyle can Control Diabetes: Wasim Akram 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 3Health News:Tune Your Brain to Hear Another in a Noisy Ambience 4Health News:Age of Medical Miracles has come upon us 2
Arrow QuadPolar EP Catheter
Mayfield Triad Skull Clamp
...umin Strips provide albumin, creatinine and albumi...linitek Microalbumin product is useful to test for...ertension in order to detect early kidney disease....f the urinary albumin excretion rate, is an indica...
Clinitek Atlas Automated Urine Chemistry Analyzer (Rack)
Medicine Products: